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Effects of 12Months of Vagus Nerve Stimulation in
Treatment-Resistant Depression: A Naturalistic Study
A. John Rush, Harold A. Sackeim, Lauren B. Marangell, Mark S. George, Stephen K. Brannan,
Sonia M. Davis, Phil Lavori, Robert Howland, Mitchel A. Kling, Barry Rittberg, Linda Carpenter,
Philip Ninan, Francisco Moreno, Thomas Schwartz, Charles Conway, Michael Burke, and John J. Barry
Background: The need for effective, long-term treatment for recurrent or chronic, treatment-resistant depression is well established.
Methods: This naturalistic follow-up describes outpatients with nonpsychotic major depressive (n  185) or bipolar (I or II) disorder,
depressed phase (n  20) who initially received 10 weeks of active (n  110) or sham vagus nerve stimulation (VNS) (n  95). The
initial active group received another 9 months, while the initial sham group received 12 months of VNS. Participants received
antidepressant treatments and VNS, both of which could be adjusted.
Results: The primary analysis (repeated measures linear regression) revealed a significant reduction in 24-item Hamilton Rating
Scale for Depression (HRSD24) scores (average improvement, .45 points [SE  .05] per month (p  .001). At exit, HRSD24 response rate
was 27.2% (55/202); remission rate (HRSD24 9) was 15.8% (32/202). Montgomery A¨sberg Depression Rating Scale (28.2% [57/202])
and Clinical Global Impression-Improvement (34.0% [68/200]) showed similar response rates. Voice alteration, dyspnea, and neck
pain were the most frequently reported adverse events.
Conclusions: These 1-year open trial data found VNS to be well tolerated, suggesting a potential long-term, growing benefit in
treatment-resistant depression, albeit in the context of changes in depression treatments. Comparative long-term data are needed to
determine whether these benefits can be attributed to VNS.
KeyWords:Vagus nerve stimulation (VNS),major depressive disor-
der, bipolar disorder, treatment-resistant depression (TRD), clinical
trial, efficacy, side effects
Treatment-resistant depression (TRD) is common. Theneed for better long-term effective treatments is sug-gested by multiple attempts to establish sequences of
treatments (algorithms) that recommend the next best steps
when first or subsequent treatments prove inadequate (e.g.,
Adli et al 2002; Bauer et al 2002; Fava et al 2003; Katon et al
1995; Linden et al 1994; Rush et al 2003, 2004a), and by
controlled trials attempting to define prospectively the next
best treatment steps (Fava et al 2003; Rush et al 2004a).
Indeed, treatment resistance is the primary indication for some
treatments, such as electroconvulsive therapy (ECT) (Ameri-
can Psychiatric Association 2000). The rationale for consider-
ing vagus nerve stimulation therapy (VNS) as a potentially
effective long-term treatment for TRD—especially for patients
with a chronic or recurrent course of illness—was presented
previously (George et al 2000, Rush et al, this issue; Rush et al
2002; Sackeim et al 2001a).
This study examined the symptomatic outcomes associated
with providing VNS as an adjunct to ongoing antidepressant
treatments over a 12-month period. Because VNS is delivered by
an implanted device with a battery life of 6 to 9 years and
because TRD is a long-term illness, the longer-term effects of
VNS among patients in treatment-resistant major depressive
episodes (MDEs) are of particular interest. Previous naturalistic
studies of VNS in patients with epilepsy have suggested that
seizure reduction, improvements in quality of life, and tolerabil-
ity of side effects increase over time (DeGiorgio et al 2000;
George et al 1994; Morris and Mueller 1999; Salinsky et al 1996;
Vonck et al 1999).
This naturalistic, 1-year study was designed to (1) determine
whether statistically significant and clinically meaningful symp-
tom reductions occur with VNS, and (2) examine the longer-term
tolerability and safety of VNS. Participants included in the
analysis of this 12-month study had been randomized to receive
either active or sham VNS during a 12-week acute phase trial
(Rush et al, this issue).
The following specific questions are addressed in this report:
1) Did depressive symptoms improve over the 12-month
observation period?
2) Were these improvements in symptoms clinically signifi-
cant and sustained?
3) Did nonVNS treatments for depression differ between
participants with clinically significant benefit and those
without such benefits?
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Methods andMaterials
Study Overview
For entry into this naturalistic phase, participants had to have
completed the acute phase randomized comparison of sham
versus active VNS (10 weeks of either sham or active VNS
delivered after 2 weeks of recovery from device implantation)
(Rush et al, this issue). The IRB approvals and informed consents
obtained at the beginning of the 12-week acute study (Rush et al,
this issue) included consent for participation in this naturalistic
follow-up portion of the study (see acknowledgments). Individ-
uals who initially received sham VNS had to requalify to be
included in these 12-month analyses. Requalification required
having two Hamilton Rating Scale-Depression (HRSD24) (Ham-
ilton 1960, 1967) assessments after 8 and 10 weeks of sham VNS
(to establish a baseline before activation of the VNS device), with
an average score of18 over these two assessments. Participants
who initially received sham VNS, but whose average scores were
18, were not eligible for this analysis, but they could elect to
receive active VNS for humanitarian reasons.
Those who initially received active VNS in the randomized
acute trial and who continued in this study received an additional
9 months of VNS. To be included in this evaluable (efficacy)
sample, all participants had to have at least one HRSD24 assess-
ment after completing the acute phase study. The degree of
treatment resistance was gauged by the number of unsuccessful
treatments according to the Antidepressant Treatment History
Form (ATHF) qualified trials in the current MDE (Oquendo et al
1999; Prudic et al 1990, 1996; Sackeim et al 1990, 2000, 2001a).
Outcome Evaluations
The primary outcome measure was change over time in the
scores of the HRSD24 (Hamilton 1960, 1967). The reliability of the
clinical evaluators’ HRSD24 ratings has been reported (Rush et al,
this issue). Secondary outcome measures included the 10-item
Montgomery Asberg Depression Rating Scale (MADRS) (Mont-
gomery and Asberg 1979), the Clinical Global Impression Scale
(Severity – CGI-S and Improvement – CGI-I) subscales (Guy W
1976), and the 30-item Inventory of Depressive Symptomatology
– Self-Report (IDS-SR30) (Rush et al 1996, 2000; 2005; Trivedi et al
2004). The 11-item Young Mania Rating Scale (Young et al 1978)
was used to assess manic/hypomanic symptoms.
For participants initially randomized to active VNS, the base-
line HRSD24, MADRS, IDS-SR30, YMRS, and CGI-S scores were
the averages of the two assessments before implantation.
For those who initially received sham VNS, a new baseline
was established by averaging these ratings obtained after 8 and
10 weeks of sham VNS. For this group, ratings for the HRSD24,
MADRS, IDS-SR30, and YMRS were obtained just before VNS
activation, and after 1, 2, 3, 4, 6, 8, and 10 weeks of VNS. The
CGI-I was collected just before initiating active VNS for the sham
group, and after 10 weeks of VNS. After 10 weeks of active VNS
had been delivered to each participant, assessments with the
HRSD24, MADRS, IDS-SR30, YMRS, and CGI-I were obtained
monthly for the ensuing 9 months.
During the 12-month study, clinical raters obtaining the CGI,
HRSD24, and MADRS were masked to VNS parameter settings
and to concomitant medications. These clinical raters were not
involved in the clinical care of the participants. An unblinded
staff member, who collected information on AEs, turned off the
VNS device before all clinical ratings were obtained.
Adverse events were collected by the COSTART system
(Coding Symbols for Thesaurus of Adverse Reaction Terms)
(Food and Drug Administration 1995). Treatment-emergent ad-
verse events (AEs) were defined as those events occurring on or
after the date of implantation, not reported as baseline signs/
symptoms, and worsening in severity or frequency. Furthermore,
the emergence of mania was monitored with the YMRS. The
presence of mania was determined by a YMRS score of 15, and
DSM-IV criteria. For this study, mania had to be deemed related
to stimulation to be considered an AE.
VNS and Concomitant Treatments
Active VNS therapy was delivered according to the protocol
previously specified (Rush et al, this issue) during the initial 10
weeks (both for participants initially receiving active VNS ther-
apy and those initially receiving sham VNS). Device program-
ming and integrity were checked at each acute phase visit and
monthly during the follow-up period.
After 10 weeks of active VNS (for both the initial sham and
active VNS groups), VNS stimulation parameters could be ad-
justed during the ensuing 9 months. Although changes to any
setting within the device programming range were allowed, most
participants stayed on the original acute-phase VNS settings,
except for output current (which typically increased). For the
safety sample (n  233), median settings after 3 months of VNS
were .75 mA (range, .00 to 2.00 mA); 20 Hz (range, 5 to 30 Hz);
500 sec (range, 130 to 750 sec); 30 sec ON (range, 7 to 30 sec);
and 5 min OFF (range, .20 to 180 min). By 12 months the median
settings were output current, 1.0 mA, (range, .0 to 2.25 mA);
frequency, 20 Hz, (range, 2 to 30 Hz); pulse width, 500 sec,
(range, 130 to 750 sec); ON time, 30 sec (range, 7 to 60 sec); and
OFF time, 5 min OFF (range, .3 to 180 min).
The protocol allowed changes in the types or doses of any
psychotropic or other medications after 10 weeks of active VNS
for both groups. Concomitant medications and other treatments
were recorded at each study visit. In addition, other somatic
treatments, e.g., ECT and rTMS, were allowed, as was the
addition or deletion of psychotherapy. In many cases, VNS was
monitored and adjusted by the study investigator, while medica-
tions and other treatments were decided by the participant’s
regular (noninvestigator) health care provider. In other cases, the
VNS investigator also managed all of the participant’s treatments.
Statistical Methods
Quintiles Inc. (Research Triangle Park, Durham, North Caro-
lina), a clinical research organization (CRO), primarily conducted
clinical monitoring visits. Data were entered, verified, and ana-
lyzed using procedures that ensured the accuracy of the data and
results. The a priori specified primary outcome is a repeated
measures analysis of the HRSD24 total score, which estimated the
average monthly change in HRSD24 over 12 months of stimula-
tion. Months of stimulation were segmented into four quarters of
3 months each, so that a separate slope for change in HRSD24 per
month was calculated for each quarter, and an overall estimate
was calculated by averaging the change across the four seg-
ments. The model adjusted for baseline HRSD24, acute study
treatment group (those originally randomized to active or
sham), and pooled site. Sites were pooled before unblinding
into four groups for statistical adjustment, such that sites
enrolling a similar number of participants were combined in
the same pooled site. To handle unequally spaced visits, the
correlation of the repeated measurements was modeled with a
spatial power covariance structure including a measurement
error component. The repeated measures analysis was also
completed for the IDS-SR30.
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To assess clinical relevance, response was defined a priori as
a reduction of 50% or more in the score compared with baseline
for the HRSD24, IDS-SR30, or MADRS, or a CGI-I of 1 or 2 (much
or very much improved). Remission was defined a priori as a
score 9 on the HRSD24, 14 for the IDS-SR30, or 10 on the
MADRS. In the calculation of response and remission rates,
participants who exited because of VNS therapy-related adverse
events (AEs) or lack of efficacy, met suicide exclusion criteria,
attempted suicide that resulted in significant (3 days) hospital-
ization, or developed mania or four or more periods of mood
rapid cycling were declared treatment failures. Change in re-
sponse status from 3 months to 12 months and exit using last
observation carried forward (LOCF) were evaluated for statistical
significance via McNemar’s test.
Because this manuscript concentrates on the period between
the end of the acute phase to 12-month exit, an LOCF analysis of
the period between 3 and 12 months was used. Participants who
lacked scores for an evaluation (e.g., MADRS) at 3 months could
not be included in this analysis, thus accounting for the number
of participants being slightly less than 205.
To further assess the clinical relevance of symptom improve-
ment, we described the durability of benefit by defining a
“sustained response” a priori as achieving at least a 50%
reduction in baseline symptoms (HRSD24) at least once during
the last quarter (months 9, 10, 11, or 12), and achieving at least
a 40% reduction from baseline on at least two other of the
HRSD24 assessments in the quarter. The reason for the40% rule
was to remove the effects of error of measurement or minor
symptomatic change on response rates, while also requiring at
least a clinically significant symptom reduction on the other.
Relationship of NonVNS Treatments to Outcome
To evaluate the potential relevance of concomitant treatment
on longer-term outcomes, HRSD24 responders and nonre-
sponders at exit (LOCF) were compared for changes in nonVNS
mood disorder treatments (categorized as removed/decreased
dose, no change, or added/increased dose) with a Mantel-
Haenszel Chi-square test for ordinal data using standardized
midranks.
Statistical significance was set at p  .050. Inferential conclu-
sions regarding VNS effectiveness in this study were limited to
the single a priori primary outcome (repeated measures of
HRSD24). We interpreted p-values from all secondary outcomes
as descriptive in nature; no adjustments were made for multiple
comparisons.
Results
Sample Development
The evaluable (n  205) sample was developed from the
implanted/randomized sample (n  235). Of these 235 partici-
pants, two participants were not included in this analysis of the
12-month outcomes (one because of suicide during the acute
phase; one because of device explantation secondary to infec-
tion during the acute phase). The remaining 233 participants
formed the 12-month safety sample.
Of these 233 participants, 28 were not evaluable for efficacy.
Three participants had HRSD24 scores 18 after implantation,
four participants in the initial active VNS group had no HRSD24
scores after acute phase exit, and 21 initial sham participants did
not average 18 on the HRSD24 at 8 and 10 weeks of sham
treatment. The exclusion of the initial sham participants who
scored 18 at the end of acute phase sham VNS provided a
conservative estimate of longer-term effects. The remaining 205
participants formed the evaluable (efficacy) sample for the
12-month analyses in this report.
The completer sample was developed from the 205 evaluable
participants. Of 205 evaluable participants, 17 discontinued partici-
pation before 1 year (four because of adverse events; seven because
of lack of efficacy, six because of other participant decisions), six
did not have stimulation 80% of the time, and five had neither
an 11- nor 12-month HRSD24 score. The remaining 177 partici-
pants constituted the completer sample.
In addition to LOCF analyses performed for the 177 partici-
pants who completed the 12-month study, analyses also were
performed using an observed sample. For the observed sample,
only participants with data available for each measurement at
each time point were included, thus the n may vary.
Sample Characteristics
Table 1 describes the evaluable (n  205) sample. Most
participants had MDD with a substantial degree of treatment
Table 1. Baseline Demographics and Clinical Features
Parameter Evaluable (n 205)
Mean Age in Years [mean (SD)] 46.3 (8.9) (median 47.0)
% Female 63.9
% Caucasian 96.6
%MDD 90.2
% Bipolar I or II 9.8
%With Recurrent MDD (n) 78.5 (161/205)
%With single-episode MDD (n) 11.7 (24/205)
% Attempted Suicide (Lifetime) 31.7 (65/205)
Length of Current MDE (Months) [mean (SD)] 49.9 (52.1) (median 34.0)
% In Current MDE2 Years 68.3 (140/205)
Age at Onset of First Mood Episode (years)
[mean (SD)]
21.8 (11.9)
Length of Illness (Years) [mean (SD)] 25.5 (11.9) (median 25.5)
Number of Failed ATHF Trials, Current MDE
[mean (SD)]
3.5 (1.3)
% ECT In Lifetime 52.7
% ECT In Current MDE 35.1
Lifetime Hospitalizations for Mood Disorder
[mean (SD)]
2.7 (5.4) (median 1.0)
Baseline HRSD24 [mean (SD)]
a 28.0 5.7
Baseline MADRS [mean (SD)]a 30.8 6.9
Baseline IDS-SR30 [mean (SD)]
a 42.9 10.0
Lifetime MDEs (%)
0–2 24.4
3–5 33.7
6–10 27.3
10 9.3
Unknown 5.4
%With Unsuccessful ATHF Trialsb
2–3 56.6 (116/205)
4–5 35.1 (72/205)
6 8.3 (17/205)
MDD,major depressive disorder; MDE, major depressive episode; ATHF,
Antidepressant Treatment History Form; ECT, electroconvulsive therapy;
HRSD24, 24-item Hamilton Rating Scale for Depression; MADRS, Montgom-
ery-Asberg Depression Rating Scale; IDS-SR30, 30-item Inventory of Depres-
sive Symptomatology-Self Report.
aFor participantswho receivedVNS at randomization, severitymeasures
were obtained at baseline before implantation. For those who initially re-
ceived sham treatment, baseline severity measures were the average of
those obtained after 8 and 10 weeks of sham treatment.
bIn current MDE.
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resistance. Table 2 shows the proportion of participants treated
in both the current MDE and in their lifetimes with different
groups of psychotropic agents. Most participants had received
two or more SSRIs (for the current episode, 53.7% (110/205); for
lifetime, 91.7% (188/205)). This participant group had long-
standing illness (more than 25 years), with a substantial propor-
tion having been hospitalized, having received ECT, and having
an extensive exposure to a wide variety of medications.
Did Symptoms Improve Over the 12-Month Observation
Period?
For the primary analysis, 205 patients provided data at 3
months, 197 at 6 months, 186 at 9 months, and 181 at 12 months.
Figure 1 shows the observed HRSD24 average at each time point
as well as estimates from the repeated measures regression
model for the evaluable sample. On average, the HRSD24 score
improved .45 (SE  .05) points per month (repeated measures
t  8.25, df  654, p  .001). Based on the evaluable sample
(n  205), all quarters showed an improvement over time, with
the largest average monthly increase seen in the first quarter
(1.22 points, SE  .17, repeated measures t  7.29, df  793,
p  .001).
Improvement in the third quarter was also statistically signif-
icant (.45 points, SE .18, repeated measures t 2.54, df 972,
p  .011) Similar results were obtained with the IDS-SR30
(average improvement per month  .52 points (SE  .08,
repeated measures t  6.79, df  631, p  .001). Table 3 lists the
mean scores of the HRSD24, IDS-SR30, and MADRS at baseline
and 12 months. All three measures reveal statistically significant
reductions over 12 months.
A comparison of the participants who had been randomized
to the control group with those who received stimulation during
the acute phase of this study (intent to treat sample) showed that
for the sham group, HRSD24 scores were lower at baseline (mean
HRSD24 of 24.6 vs. 28.7; t-test t  4.55, df  227, p  .001) and
the sham group did not improve as much over time (active vs.
sham estimate of HRSD24 averaged across all time points 
1.96, SE .63; repeated measures t 3.14, df 253, p .002).
Were the Improvements in Depressive Symptoms Clinically
Meaningful?
We conducted several appraisals of the clinical importance of
this symptomatic improvement. Figure 2 shows the response and
remission rates for the HRSD24, MADRS, and IDS-SR30 at 3, 6, 9,
and 12 months and LOCF beyond 3 months. Recall that an LOCF
analysis of the period between 3 and 12 months was used. For
HRSD24, 27.2% (55/202) participants achieved a response at exit
(LOCF), and 15.8% (32/202) achieved a remission. For the
observed participants, the HRSD24 response rate after 12 months
was 29.8% (54/181), while the HRSD24 remission rate was 17.1%
(31/181).
Similar response and remission rates were obtained with the
MADRS (response of 28.2% for LOCF [57/202] and of 31.5% for
observed evaluable [57/181]; remission of 20.3% for LOCF [41/
202] and of 22.7% for observed evaluable [41/181]) and the
IDS-SR30 (response of 19.9% for LOCF [40/201] and of 21.7% for
observed [39/180]; remission of 13.4% for LOCF [27/201] and of
15.0% for observed [27/180]).
Figure 2 shows that the response rates (HRSD24 and MADRS)
and the remission rates (HRSD24, MADRS, and the IDS-SR30)
doubled from 3 to 12 months. Changes in response and remis-
sion status from 3 months to 12 months and exit (LOCF) were
statistically significant for HRSD24 and MADRS based on McNe-
mar’s test (all p-values .005). The CGI-I ratings confirmed these
findings with 19.6% (39/199) participants at 3 months, 24.9%
(49/197) at 6 months, 27.7% (51/184) at 9 months, and 36.5%
(66/181) at 12 months rated as 1 or 2 (very much or much
improved; evaluable sample, 34.0% [68/200] LOCF). This in-
crease in both response and remission rates is not attributable to
participant attrition because the LOCF response and remission
rates also reflected an increasing proportion of responders and
remitters from 3 months to study exit.
To further examine clinical benefit, we calculated the percent-
age of participants in the completer sample (n  177) with a
“sustained response” using the HRSD24 data at months 9, 10, 11,
and 12. At least one visit had to show a 50% reduction in
baseline HRSD24 total score, and another two of these visits had
to achieve at least a 40% reduction in baseline total score. Of
the completer sample (LOCF), 29.4% (52/177) participants had a
response at 12 months and 26.6% (47/177) participants had a
“sustained response.” Of the 52 participants who were respond-
ers at 12 months, 73.1% (38/52) were also “sustained respond-
ers.” Of the 47 participants with a “sustained response,” 66%
(31/47) met the criteria for response at all 4 points (9. 10, 11, and
12 months).
Did NonVNS Treatments Differ between Participants with and
without Clinical Benefits?
We divided the sample into responders and nonresponders
based on the HRSD24 at exit (LOCF, n 205). Of the responders,
5.5% (3/55) were on no concomitant medications, while none of
the 150 nonresponders were on no medication (Mantel Haenszel
2 (1 df)  8.3, p  .0040). Medications were removed or
decreased only (no additions or dose increases) in 12.7% (7/55)
responders and in 9.3% (14/150) nonresponders. Altogether
30.9% (17/55) responders (including the three responders who
received no concomitant medications) had no medication
changes as compared with 14.0% (21/150) nonresponders. Fi-
nally, 56.4% (31/55) responders had either an increase in dose or
had a medication added as compared with 76.7% (115/150)
nonresponders. The nonresponders had significantly more med-
ication changes/dose increases compared with the responders
(Mantel Haenszel 2 (1 df)  8.054, p  .005).
Adverse Events
Two participants discontinued treatment during the first 3
months of VNS (one because of suicide after 5 weeks of active
Table 2. Proportion of Participants Who Received Various Psychotropic
Treatments (Current MDE and Lifetime; n 205)
Treatment Current MDE (%) Lifetime (%)
Heterocyclics/TCAs 50.2 83.4
SSRIs 90.2 99
MAOIs 24.4 42.4
Other Antidepressantsa 93.7 99
Lithium 36.6 66.3
Anticonvulsants 51.7 62.4
Stimulants 43.4 55.1
Atypical Antipsychotics 41.5 48.3
Non atypical Antipsychotics 10.7 34.6
Otherb 45.4 56.6
ECT 35.1 52.7
MDE, major depressive episode; TCA, tricyclic antidepressants; SSRI, se-
lective serotionin reuptake inhibitor; MAOI, monoamine oxidase inhibitor;
ECT, electroconvlsive therapy.
aIncludes, for example, bupropion, nefazodone, mirtazapine.
bIncludes, for example, St. John’sWort, SAMe, cognitive therapy, benzo-
diazepines.
358 BIOL PSYCHIATRY 2005;58:355–363 A.J. Rush et al
www.sobp.org/journal
stimulation and one because of wound infection that required
device removal). The participant who committed suicide after
receiving about 5 weeks of VNS had, before entering the study,
attempted suicide once and had been hospitalized for depression
on three occasions. The remaining 233 implanted participants
were analyzed for long-term safety. Twenty-four (24) participants
discontinued during the 12-month phase: seven for adverse
events of which two were deaths (see below), and 17 for lack of
efficacy or other reasons.
One death due to esophageal cancer occurred before device
implantation; one suicide (mentioned previously) occurred dur-
ing the acute phase of the study, after 5 weeks of active VNS. One
additional death occurred during the subsequent 9 months of
VNS. A 61-year-old Caucasian female participant with bipolar
disorder was found dead of unknown causes. An autopsy was
not performed, but the coroner saw no evidence of homicide or
suicide.
Table 4 summarizes stimulation-related AEs observed at 5%
incidence by quarter. At 3 months of VNS, the stimulation-related
AEs reported with the greatest frequency were voice alteration,
increased cough, neck pain, dyspnea, and dysphasia. After 12
months of VNS, the frequency of reported AEs held constant or
decreased. Voice alteration remained the most frequently re-
ported, followed by dyspnea and neck pain.
VNS was generally well tolerated with either a reduction or no
increase in adverse events from 3 to 12 months of VNS. Rates of
dysphagia, 13% during the first quarter, decreased to 4% by the
fourth quarter. Paresthesia (from 11% to 4%), increased cough
(from 24% to 6%), and laryngismus (from 10% to 5%) decreased
between the first and fourth quarters. The most frequently
reported adverse event, voice alteration, remained fairly constant
over the study period (reported by more than half the participants
during each quarter). Altogether, these data suggest that VNS is well
tolerated and most adverse events are reduced over time.
Development of Mania/Hypomania. Three participants de-
veloped manic symptoms that met criteria (YMRS 15 and
confirmed by DSM-IV) (two during the first 3 months and one
during the subsequent 9 months of VNS). Both participants who
developed manic symptoms during the first 3 months of VNS had
mild symptoms that resolved in 1 to 2 weeks. One participant
had a bipolar diagnosis, and one had a history of treatment-
induced mania. The first participant experienced manic symp-
toms when stimulation was initiated. By the time of the next visit,
the symptoms had subsided and device parameters were in-
creased from .25 to .50 mA. VNS parameters were not changed
for the second participant whose parameters remained at .75 mA
during the episode. The participant with a manic reaction during
the subsequent 9 months of VNS had a diagnosis of unipolar
depression at baseline. Stimulation, which was 2.25 mA when the
episode began, was stopped on the day that the participant was
hospitalized. Stimulation remained off during the episode, which
lasted about 2 months, and was restarted at .50 mA about a
month after the episode ended, increased to 1.00 mA about 2
weeks later, and increased to 1.50 mA about 2 additional weeks
later.
Three additional participants had an elevated YMRS score
(15) after the first 3 months of VNS, but they did not meet
DSM-IV criteria. Two of these participants had bipolar disorder.
These hypomanic symptoms were brief (1 to 3 days) and
subsided without changes in medication dose or type or VNS
settings.
There was no clinically meaningful change in systolic or
diastolic blood pressure, heart rate, respiration rate, or weight
(baseline to exit). Of the 172 participants on whom body weight
was available, 21 (12.2%) participants had gained more than 7%
of their baseline body weight by study exit, and 23 (13.4%)
participants had lost more than 7% of their baseline body weight
by study exit.
Worsening of Depression. During the 12-month study, 30
participants had worsening of depression sufficient to require
hospitalization. Of these 30 participants, 24 (80%) had a history
of hospitalization for worsening depression before study enroll-
Figure 1. Observed and predicted average HRSD24
evaluable sample (n  205). Predicted values are
basedon repeatedmeasures linear regressionof the
HRSD24 total score atWeeks 1, 3, 6, 8, 10 andMonths
4-12 of stimulation with a spatial power covariance
structure, and with fixed effects for pre-stimulation
baseline HRSD24. Acute treatment group, pooled
site indicator variables, and months of stimulation
segmented into 4 quarters. The predicted average
HRSD24 values and 95% CI represent a hypothetical
patientwithaveragepre-stimulationHRSD24 values;
with an averaging across treatment groups and
pooled sites. HRSD24, 24-itemHamilton Rating Scale
for Depression.
Table 3. Symptom Ratings at Baseline and 12 Months (Mean and SD)
Baseline 12 Months (Observed) 12 Months (LOCF) p-valuea
HRSD24 28.0  5.7 (n  205) 19.6 9.7 (n  180) 20.6 9.9 (n  205) .001
IDS-SR30 42.9  10.0 (n  204) 32.6 15.3 (n  180) 33.6 15.4 (n  204) .001
MADRS 30.8 6.9 (n  205) 21.2 11.5 (n  181) 22.2 11.7 (n  205) .001
HRSD24, 24-item Hamilton Rating Scale for Depression; IDS-SR30, 30-item Inventory For Depressive Symptomatol-
ogy-Self Report; MADRS, Montgomery - Asberg Depression Rating Scale.
ap-values are based on paired t-tests comparing between baseline, 12 months (observed), and 12 months LOCF
(Last Observation Carried Forward). The treatment effect in repeated measures linear regressions for the HRSD and
IDS-SR also resulted in p .001.
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ment. Further, the percentage of participants with worsening of
depression based on the HRSD24 ratings of 0% reduction from
baseline (i.e., worsening), decreased over time: 27.1% (48/177,
completer sample) at 3 months, 25.1% (44/175) at 6 months,
18.1% (31/171) at 9 months, and 17.2% (30/174) at 1 year
(observed cases).
Two participants each made one suicide attempt (one coded
by COSTART as an overdose) during the first 3 months of
receiving VNS, and five participants made six suicide attempts
over the ensuing 9 months of VNS (one participant made two
attempts). One attempt occurred after 3 months of VNS, one after
4 months, three after 5 months, and one after 11 months. The
participant who attempted suicide twice made both attempts
after 5 months of VNS (the attempts occurred about 2 weeks
apart). Of the seven participants who attempted suicide, four
(57.1%) had a prior history of at least one suicide attempt.
Discussion
This 12-month study (n  205) of VNS used as an adjunct to
other antidepressant treatments in patients with treatment-resis-
tant, chronic or recurrent mood disorders revealed statistically
significant reductions in depressive symptoms. The primary
repeated measures linear regression analysis of the evaluable
sample revealed a statistically significant reduction over time in
both the HRSD24 total scores and the IDS-SR30 total scores.
The clinical relevance of the symptom reduction was demon-
strated by the response and remission rates of several measures.
For example, the HRSD24 revealed that 27.2% (55/202) of
evaluable participants achieved a response at exit (LOCF) and
15.8% (32/202) achieved a remission. Similar results were ob-
tained with the MADRS: 28.2% (57/202) response and 20.3%
(41/202) remission. Furthermore, most (73.1%) of those with a
Figure 2. HRSD24, MADRS, and IDS-SR30 response
and remission rates [evaluable participants*]. *The
number of participants varies by time interval as
based on observed-case analyses. The range for the
number of participants with available data at each
time interval is provided. **An LOCF analysis of the
period between 3 and 12 months was used. Partici-
pants who lacked scores for an evaluation at 3
months could not be included in this analysis, thus
accounting for the number of participants being
slightly less than205.HRSD24, 24-itemHamiltonRat-
ing Scale for Depression; MADRS, Montgomery-As-
berg Depression Rating Scale; IDS-SR30, 30-item In-
ventory of Depressive Symptomatology-Self-
Report.
Table 4. Prevalence of Observed Stimulation-Related AEs at5% Incidence by Quartersa
3 Mos (n 232)b 6 Mos (n 225)b 9 Mos (n 218)b 12 Mos (n 209)b
Adverse Event
Headache 12 (5%) 9 (4%) 9 (4%) 8 (4%)
Neck pain 38 (16%) 25 (11%) 31 (14%) 27 (13%)
Pain 13 (6%) 14 (6%) 11 (5%) 13 (6%)
Dysphagia 31 (13%) 19 (8%) 15 (7%) 9 (4%)
Nausea 13 (6%) 5 (2%) 5 (2%) 4 (2%)
Insomnia 10 (4%) 5 (2%) 6 (3%) 2 (1%)
Paresthesia 26 (11%) 15 (7%) 7 (3%) 9 (4%)
Cough increased 55 (24%) 20 (9%) 15 (7%) 13 (6%)
Dyspnea 33 (14%) 35 (16%) 33 (15%) 34 (16%)
Laryngismus 23 (10%) 18 (8%) 16 (7%) 10 (5%)
Pharyingitis 14 (6%) 8 (4%) 8 (4%) 11 (5%)
Voice alteration 135 (58%) 135 (60%) 125 (57%) 113 (54%)
Serious Adverse Event
Mania 2 (1%) 1 (1%) 0 0
Suicide attempts 2 (1%) 3 (1%) 1 (1%)c 1 (1%)
Worsening depression 12 (5.2%) 15 (6.7%) 10 (4.6%) 12 (5.7%)
Hospitalizations 13 19 14 14
AE, adverse event.
aTallies are provided by quarter. Participants may have had multiple events across the 12-month study.
bNumber of participants reporting during the particular interval.
cTwo attempts.
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response by HRSD24 during the final quarter of stimulation met
our a priori definition of a “sustained HRSD24 response.”
There was a general pattern of increasing response rates
observed at 3, 6, 9, and 12 months based on the HRSD24, CGI-I,
MADRS, and IDS-SR30. For example, CGI-I ratings revealed an
increase in response rates from 19.6% at 3 months to 34.0%
(LOCF) at 12 months. A statistically significant increase in re-
sponse rates was seen between 3 and 12 months (LOCF) for
HRSD24 and MADRS (p  .005).
Three participants experienced a manic syndrome over the 12
months of this study. Of these, one had a baseline diagnosis of
bipolar disorder and one had a history of treatment-induced
mania. An additional three participants developed hypomanic
symptoms within 3 months of starting VNS that were not
sufficient to meet DSM-IV TR criteria for a manic episode, of
which two had a bipolar disorder diagnosis at baseline. Some
investigators would view the tendency of a treatment such as
VNS to induce manic or hypomanic symptoms as evidence of
antidepressant activity (Goodwin and Jamison 1990).
VNS was generally well tolerated. Adverse events were quite
similar to those reported in both TRD and epilepsy patients
(Morris and Mueller 1999; Sackeim et al 2001b; Vagus Nerve
Stimulation Study Group 1995). The prevalence of side effects
remained constant or decreased over the 1-year study. Data
based on worsening of depression as defined by a worsening of
the HRSD24 total score do not suggest an increasing risk of
worsening of depression over time with continuing VNS.
Three deaths occurred (one due to suicide after 5 weeks of
VNS, one due to cancer before implantation, one due to un-
known causes after 10 weeks of VNS). While 30 participants
required hospitalization for worsened depression, 24 had a
history of being hospitalized for such an event before the study.
Seven participants attempted suicide, of whom four had made
attempts prior to the study.
This group of highly chronic or recurrent, treatment-resistant
participants has rarely been the subject of such long-term
investigations. The 1-year outcomes of this open trial suggest that
12 months of VNS is associated with clinically meaningful
antidepressant effects. This study has several limitations. They
include 1) nonmasked ratings, 2) lack of an active treatment
control group, and 3) the fact that treatments could be adjusted
or changed after the initial 3 months of VNS.
Could the long-term improvements be due to placebo effects?
This possibility is unlikely because one would have to believe
that placebo effects would increase over time, that they would be
largely sustained, and that they would occur in 20% to 35% of
such treatment resistant, chronically ill participants. In fact,
placebo effects are known to be seen acutely in nonTRD and to
wane, rather than increase, over time (Quitkin et al 1987).
The longer-term improvements in this study could have been
a result of a naturally occurring improvement in depression, but,
given the treatment-resistant nature of the sample, such a cause
and effect seems very unlikely. Furthermore, long-term medica-
tion trials uniformly reveal a decrease, rather than an increase, in
efficacy over time with medication even in nonTRD patients.
Continuing on medication in the long term in nonTRD patients
who respond acutely is associated with a 10% to 40% relapse/
recurrence rate (Greden 2001). In addition, spontaneous im-
provement that grows over time is very unusual in these types of
patients (Rush et al 2004b).
Could medication changes have caused the improvement that
increased over the 12-month observation period? An examina-
tion of medication changes over the 12-month observation
period revealed fewer medication changes or dose increases in
VNS responders than in VNS nonresponders. This finding sug-
gests that medication changes are not likely the cause of the
responses observed over the 12-month period. Of course, these
medication changes cannot be dissociated from the concurrent
use of VNS. That is, VNS may have increased the efficacy of
medications that otherwise would not have been effective.
However, medication changes were less frequent among VNS
responders than among VNS nonresponders, and three VNS
responders were on no medication at all from baseline to exit. In
addition, George et al (this issue) reported that those without
medication changes accounted for virtually all of the improve-
ments seen over time.
Without a control or comparison group, however, one
cannot be totally certain that these longer-term clinically
meaningful benefits are attributable to VNS. On the other
hand, let us consider nonchronic, nontreatment-resistant de-
pressed patients, the vast majority of whom have never been
hospitalized. About 50% of these patients respond to acute
treatment (Depression Guideline Panel 1993). Of these re-
sponders, roughly 25% relapse or recur over 9 to 12 months
(Greden 2001). Thus, only 38.5% of the original sample will
evidence a response at 1 year. In this context, the 25% to 33%
response rates achieved after 1 year of VNS are impressive,
especially since over 70% of those responses were “sustained”
between 9 and 12 months. George et al (this issue) provide
outcome data on a comparable group of chronically ill,
treatment-resistant depressed patients who were actively
treated without receiving VNS for 1 year.
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